Natural Investments LLC Has $1.05 Million Stake in Amgen Inc. $AMGN

Key Points

• Natural Investments LLC has reduced its stake in Amgen Inc. by 20.8% in the second quarter, now holding shares worth approximately $1.05 million.
• Amgen's stock fell by 1.8%, with the company reporting a 9.4% annual increase in quarterly revenue and earnings per share of $6.02 that exceeded estimates.
• In recent analyst activity, a significant number of firms have issued mixed ratings on Amgen, highlighting a change from "buy" to "hold" by Wall Street Zen, while others have raised their price targets.

Natural Investments LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 20.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,752 shares of the medical research company's stock after selling 985 shares during the quarter. Natural Investments LLC's holdings in Amgen were worth $1,047,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. OLD National Bancorp IN grew its position in shares of Amgen by 296.2% during the 2nd quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company's stock worth $5,027,000 after buying an additional 13,460 shares during the period. KPP Advisory Services LLC grew its position in shares of Amgen by 87.1% during the 1st quarter. KPP Advisory Services LLC now owns 5,833 shares of the medical research company's stock worth $1,817,000 after buying an additional 2,716 shares during the period. Advisor Resource Council acquired a new stake in shares of Amgen during the 1st quarter worth approximately $1,331,000. Trinity Legacy Partners LLC grew its position in shares of Amgen by 3.9% during the 1st quarter. Trinity Legacy Partners LLC now owns 16,132 shares of the medical research company's stock worth $5,026,000 after buying an additional 612 shares during the period. Finally, DLK Investment Management LLC boosted its stake in Amgen by 7.3% during the 1st quarter. DLK Investment Management LLC now owns 20,491 shares of the medical research company's stock worth $6,384,000 after acquiring an additional 1,387 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Down 1.8%

Amgen stock opened at $290.13 on Friday. The stock has a market capitalization of $156.19 billion, a PE ratio of 23.72, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The company has a 50 day moving average of $286.77 and a 200-day moving average of $287.68.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to analysts' expectations of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.3%. The ex-dividend date was Friday, August 22nd. Amgen's dividend payout ratio is 77.84%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AMGN. Wall Street Zen lowered shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday. Piper Sandler lifted their price objective on shares of Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a research note on Monday, August 25th. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Citigroup lifted their price objective on shares of Amgen from $310.00 to $315.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 24th. Finally, Morgan Stanley lifted their price objective on shares of Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Amgen currently has an average rating of "Hold" and an average price target of $309.42.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president owned 7,209 shares of the company's stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.76% of the stock is owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.